Home
Scholarly Works
CCTG PR21: A randomized phase II study of...
Conference

CCTG PR21: A randomized phase II study of [177lu]lu-PSMA-617 verus docetaxel in patients with metastatic castration-resistant prostate cancer and PSMA-positive disease (NCT04663997)

Authors

Chi KN; Saad F; Parulekar WR; Emmenegger U; Hotte SJ; Pouliot F; Bauman G; Zukotynski KA; Peacock S; Wyatt AW

Volume

40

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Publication Date

June 1, 2022

Name of conference

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Conference place

ELECTR NETWORK

Conference start date

June 3, 2022

Conference end date

June 7, 2022

Conference proceedings

JOURNAL OF CLINICAL ONCOLOGY

Issue

16

ISSN

0732-183X

Labels

Fields of Research (FoR)

Contact the Experts team